Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 0.9710 |
| Open | 0.9700 |
| Bid | 0.9721 x 2200 |
| Ask | 1.0200 x 1400 |
| Day's range | 0.9700 - 1.0200 |
| 52-week range | 0.9000 - 9.7200 |
| Volume | |
| Avg. volume | 71,568 |
| Market cap | 8.078M |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2022. Third Quarter 2022 and Recent Corporate Highlights Initiated the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Chol
- GlobeNewswire
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). “Initiation of the randomized withdrawal per
- GlobeNewswire
Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Global Investment Conference, being held September 12-14, 2022, virtually and in-person at the Lotte New York Palace Hotel in New York, NY. The presen
